BP-897

Izvor: Wikipedia
BP-897
(IUPAC) ime
N-[4-[4-(2-metoksifenil)piperazin-1-il]butil]naftalen-2-karboksamid
Klinički podaci
Identifikatori
CAS broj 314776-92-6
ATC kod nije dodeljen
PubChem[1][2] 3038495
ChEMBL[3] CHEMBL25236 YesY
Hemijski podaci
Formula C26H31N3O2 
Mol. masa 417,542 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

BP-897 je lek koji se koristi u naučnim istraživanjima. On deluje kao umereno selektivni parcijalni agonist dopaminski D3 receptora.[4] On je uglavnom korišćen za studiranje tretmana za kokainsku adikciju.[5][6][7][8][9][10][11]

Reference[uredi - уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. doi:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. doi:10.1093/nar/gkr777. PMID 21948594.  edit
  4. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (July 1999). "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature 400 (6742): 371–5. doi:10.1038/22560. PMID 10432116. 
  5. Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (February 2001). "The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology 12 (1): 1–11. PMID 11270507. 
  6. Garcia-Ladona FJ, Cox BF (2003). "BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction". CNS Drug Reviews 9 (2): 141–58. PMID 12847556. 
  7. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH (November 2003). "Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology 28 (11): 1903–15. doi:10.1038/sj.npp.1300276. PMID 12915863. 
  8. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (November 2004). "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics 311 (2): 770–7. doi:10.1124/jpet.104.071142. PMID 15226382. 
  9. Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX (July 2005). "Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors". Synapse (New York, N.Y.) 57 (1): 17–28. doi:10.1002/syn.20152. PMID 15858839. 
  10. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaál J, Gardner EL (March 2008). "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology 196 (4): 533–42. doi:10.1007/s00213-007-0986-6. PMID 17985117. 
  11. Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P (May 2008). "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". Chemmedchem 3 (5): 788–93. doi:10.1002/cmdc.200700327. PMID 18306190. 

Spoljašnje veze[uredi - уреди]